文献リスト

1）Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001; 120: 730-3

2）Yamaya M, Azuma A, Tanaka H, et al. Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in COPD in Japan: a retrospective multicenter analysis. J Am Geriatr Soc. 2008; 56: 1358-60

3）Seemungal TAR, Wilkinson TMA, Hurst JR, et al. Longterm erythromycin therapy is associated with decreased chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 178: 1139-47

4）日本呼吸器学会COPDガイドライン第3版作成委員会．COPD（慢性閉塞性肺疾患）診断と治療のためのガイドライン第3版．東京：メディカルレビュー社；2009

5）Albert RK, Connett J, Bailey WC, et al. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-98

6）日本呼吸器学会COPDガイドライン第4版作成委員会．COPD（慢性閉塞性肺疾患）診断と治療のためのガイドライン第4版．東京：メディカルレビュー社；2012

7）Wenzel RP, Fowler AA III, Edmond MB. Antibio­tic prevention of acute exacerbation of COPD. N Engl J Med. 2012; 367: 340-7

8）Yamaya M, Azuma A, Takizawa H, et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J. 2012; 40: 485-94

9）Simoens S, Laekeman G, Decramer M. Prevention of COPD exacerbations with macrolides: A review and budget impact analysis. Respir Med. 2013; 107: 637-48

10）He ZY, Ou LM, Zhang JQ. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010; 80: 445-52

11）Blasi F, Bonardi D, Aliberti S, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010; 23: 200-7

12）Pomares X, Monton C, Espasa M, et al. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obsutruct Pulm Dis. 2011; 6: 449-56

13）Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366: 1881-90

14）McConnell SA, Amsden GW. Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. Pharmacotherapy. 1999; 19: 404-15

15）Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004; 10: 3045-53

16）Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis. 2004; 17: 113-9

17）Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995; 152: 1316-20

18）Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003; 58: 37-42

19）Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164: 1618-23

20）Kadota J, Sakito O, Kohno S, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1993; 147: 153-9

21）Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in human bronchial epithelial cells: Studies with normal and inflamed airway epithelium. Am J Respir Crit Care Med. 1997; 156: 266-71

22）Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-κB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun. 2000; 267: 124-8

23）Tamaoki J, Takeyama K, Tagaya E, et al. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother. 1995; 39: 1688-90

24）Inoue D, Kubo H, Sasaki T, et al. Erythromycin attenuates MUC5AC synthesis and secretion in cultured human tracheal cells infected with RV14. Respirology. 2008; 13: 215-20

25）Suzuki T, Yamaya M, Sekizawa K, et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med. 2002; 165: 1113-8

26）Asada M, Yoshida M, Suzuki T, et al. Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antiviral Res. 2009; 83: 191-200

27）Yamaya M, Shinya K, Hatachi Y, et al. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther. 2010; 333: 81-90

28）Anderson R, Steel HC, Cockeran R, et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother. 2007; 59: 224-9

29）Takaki M, Ushikai M, Deguchi K, et al. The role of nuclear factor-kappa B in interleukin-8 expression by human adenoidal fibroblasts. Laryngoscope. 2003; 113: 1378-85

30）Tateda K, Comte R, Pechere JC, et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001; 45: 1930-3

31）Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest. 2004; 125 (2 Suppl): 62S-69S

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp